Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Granting a Marketing Authorisation for Telotristat Ethyl

It is intended for the treatment of carcinoid syndrome diarrhoea in combination with a somatostatin analogue
04 Aug 2017
Endocrine and neuroendocrine tumours

On 20 July 2017, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting a marketing authorisation for the medicinal product telotristat ethyl (Xermelo), intended for the treatment of carcinoid syndrome diarrhoea in combination with a somatostatin analogue.

It was designated as an orphan medicinal product on 8 October 2009.

The applicant for this medicinal product is Ipsen Pharma.

It will be available as 250-mg film-coated tablets.

The active substance in Xermelo, telotristat ethyl, inhibits L-tryptophan hydroxylases (TPH1 and TPH2), which are the rate-limiting step in serotonin biosynthesis.

Serotonin is over-secreted in patients with neuroendocrine tumours and carcinoid syndrome. Serotonin is thought to contribute to the symptoms associated with carcinoid syndrome.

The benefits with telotristat ethyl are its ability to decrease the number of bowel movements per day in patients whose carcinoid syndrome diarrhoea cannot be managed  with somatostatin analogues alone.

The most common side effects are abdominal pain, fatigue and increased gamma-glutamyl transferase.

The full indication is:

"Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy".

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

Last update: 04 Aug 2017

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.